Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects

Diabetology and Metabolic Syndrome

Volumn 2, Issue 1, 2010, Pages

  Kater, Ana Lucia A ^a   Batista, Marcelo C ^a   Ferreira, Sandra R G ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; EZETIMIBE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG POTENTIATION; FEMALE; HEALTH STATUS; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL;

EID: 77954587552     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-2-34     Document Type: Article

References (31)

1. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. J Shepherd SM Cobbe I Ford CG Isles AR Lorimer PW MacFarlane JH McKillop CJ Packard, N Engl J Med 1995 333 1301 7 10.1056/NEJM199511163332001 7566020
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 1383 9 7968073
3. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. R Collins J Armitage S Parish P Sleigh R Peto Heart Protection Study Collaborative Group, Lancet 2003 361 2005 16 10.1016/S0140-6736(03)12475-0 12814710
4. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. TR Pedersen O Faergeman JJ Kastelein AG Olsson MJ Tikkanen I Holme ML Larsen FS Bendiksen C Lindahl M Szarek J Tsai Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group, JAMA 2005 294 2437 45 10.1001/jama.294.19.2437 16287954
5. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. SE Nissen EM Tuzcu P Schoenhagen BG Brown P Ganz RA Vogel T Crowe G Howard CJ Cooper B Brodie CL Grines AN DeMaria REVERSAL Investigators, JAMA 2004 291 1071 80 10.1001/jama.291.9.1071 14996776
6. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. RS Rosenson CC Tangney, JAMA 1998 279 1643 50 10.1001/jama.279.20.1643 9613915
7. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. J Musial A Undas P Gajewski M Jankowski W Sydor A Szczeklik, Int J Cardiol 2001 77 247 53 10.1016/S0167-5273(00)00439-3 11182189
8. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines [published correction appears in Circulation. 2004;110:763]. SM Grundy JI Cleeman CN Merz HB Brewer Jr LT Clark DB Hunninghake RC Pasternak SC Smith Jr NJ Stone National Heart, Lung, and Blood Institute, American College of Cardiology Foundation; American Heart Association, Circulation 2004 110 227 39 10.1161/01.CIR.0000133317.49796.0E 15249516
9. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. SC Smith Jr J Allen SN Blair RO Bonow LM Brass GC Fonarow SM Grundy L Hiratzka D Jones HM Krumholz L Mosca RC Pasternak T Pearson MA Pfeffer KA Taubert AHA/ACC; National Heart, Lung, and Blood Institute, Circulation 2006 113 2363 72 [Erratum, Circulation 2006, 113:e847.] 10.1161/CIRCULATIONAHA.106.174516 16702489
10. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. J Shepherd P Barter R Carmena P Deedwania JC Fruchart S Haffner J Hsia A Breazna J LaRosa S Grundy D Waters, DiabetesCare 2006 29 1220 26
11. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. HM Colhoun DJ Betteridge PN Durrington GA Hitman HA Neil SJ Livingstone MJ Thomason MI Mackness V Charlton-Menys JH Fuller CARDS investigators, Lancet 2004 364 685 96 10.1016/S0140-6736(04)16895-5 15325833
12. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. MH Davidson T McGarry R Bettis L Melani LJ Lipka AP LeBeaut R Suresh S Sun EP Veltri, J Am Coll Cardiol 2002 40 2125 34 10.1016/S0735-1097(02)02610-4 12505224
13. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. CM Ballantyne J Houri A Notarbartolo L Melani LJ Lipka R Suresh S Sun AP LeBeaut PT Sager EP Veltri Ezetimibe Study Group, Circulation 2003 107 2409 15 10.1161/01.CIR.0000068312.21969.C8 12719279
14. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. ME Sweeney RR Johnson, Expert Opin Drug Metab Toxicol 2007 3 441 50 10.1517/17425255.3.3.441 17539750
15. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. RH Knopp H Gitter T Truitt H Bays CV Manion LJ Lipka AP LeBeaut R Suresh B Yang EP Veltri Ezetimibe Study Group, Eur Heart J 2003 24 729 41 10.1016/S0195-668X(02)00807-2 12713767
16. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. DB Hunninghake RH Knopp G Schonfeld AC Goldberg WV Brown EJ Schaefer S Margolis AS Dobs MJ Mellies W Insull Jr, et al. Atherosclerosis 1990 85 81 9 10.1016/0021-9150(90)90185-L 2126437
17. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. PT Sager L Melani L Lipka J Strony B Yang R Suresh E Veltri Ezetimibe Study Group, Am J Cardiol 2003 92 1414 8 10.1016/j.amjcard.2003.08.048 14675576
18. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. PT Sager R Capece L Lipka J Strony B Yang R Suresh Y Mitchel E Veltri, Atherosclerosis 2005 179 361 7 10.1016/j.atherosclerosis.2004.10.021 15777554
19. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. RB Goldberg JR Guyton T Mazzone RS Weinstock A Polis P Edwards JE Tomassini AM Tershakovec, Mayo Clin Proc 2006 81 1579 88 [Erratum in: Mayo Clin Proc 2007;82:387] 10.4065/81.12.1579 17165637
20. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. T Pearson C Ballantyne C Sisk A Shah E Veltri D Maccubbin, Am J Cardiol 2007 99 1706 13 10.1016/j.amjcard.2007.01.062 17560879
21. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. ALA Kater MC Batista SRG Ferreira, Metabolism 2010 59 921 6 10.1016/j.metabol.2010.02.011 20199786
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001 285 2486 97 10.1001/jama.285.19.2486 11368702
23. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. S Devaraj E Chan I Jialal, J Clin Endocrinol Metab 2006 91 4489 96 10.1210/jc.2006-0299 16968805
24. Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced. K Pyorala D Wood, Eur Heart J 1998 19 1434 1503 10.1053/euhj.1998.1243 9820987
25. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. G Liuzzo LM Biasucci JR Gallimore RL Grillo AG Rebuzzi MB Pepys A Maseri, N Engl J Med 1994 331 417 24 10.1056/NEJM199408183310701 7880233
26. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. PM Ridker CH Hennekens JE Buring N Rifai, N Engl J Med 2000 342 836 43 10.1056/NEJM200003233421202 10733371
27. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. PM Ridker N Rifai L Rose JE Buring NR Cook, N Engl J Med 2002 347 1557 65 10.1056/NEJMoa021993 12432042
28. C-reactive protein in the prediction of cardiovascular events. MK Evans AB Zonderman WR Johnson, N Engl J Med 2003 348 1059 61 10.1056/NEJMra020526 12638580
29. Reduction in the C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. PM Ridker E Danielson FAH Fonseca J Genest AM Gotto JJ Kastelein W Koenig P Libby AJ Lorenzatti JG MacFadyen BG Nordestgaard J Shepherd JT Willerson RJ Glynn on the behalf of the JUPITER Trial Study Group, Lancet 2009 373 1175 82 10.1016/S0140-6736(09)60447-5 19329177
30. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. C Bulco FF Ribeiro-Filho A Sãudo SRG Ferreira, Am J Cardiovasc Drugs 2007 7 219 24 10.2165/00129784-200707030-00007 17610348
31. The endocrine function of adipose tissue: an update. T Ronti G Lupattelli E Mannarino, Clin Endocrinol (Oxf) 2006 64 355 65 16584505